Skip to main content
. 2019 Sep 27;18(6):5811–5820. doi: 10.3892/ol.2019.10929

Table II.

Non-hematological toxicity of the VTD regimen.

1–2 grade adverse events 3–4 grade adverse events


Non-hematological toxicity Number, n Percentage (n=205) Number, n Percentage (n=205)
Polyneuropathy
  Grade 1 36 17.6 10 4.9
  Grade 2 45 33.0
Infections 8 4.0 2 1.0
Thrombosis 7 3.4 1 0.5
Pulmonary embolism 2 1.0
Constipation 2 1.0
Skin alterations 2 1.0 3 1.5

VTD, bortezomib, thalidomide, dexamethasone.